Evidence map›Paper›PMID 34903371›Full record

ArticleVaccine2022

Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.

Brittani N Blunck, Letisha Aideyan, Xunyan Ye, Vasanthi Avadhanula, Laura Ferlic-Stark, Lynn Zechiedrich, Brian E Gilbert, Pedro A Piedra

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Efficiency of p27 Cleavage duringJournal of virology · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Brittani N BlunckDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Letisha AideyanDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Xunyan YeDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Vasanthi AvadhanulaDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Laura Ferlic-StarkDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Lynn ZechiedrichDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA.
Brian E GilbertDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Pedro A PiedraDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. Electronic address: ppiedra@bcm.edu.
Baylor College of Medicine · US

Funding

Harnessing Supercoiling to Regulate DNA ActivityR35GM141793 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ZECHIEDRICH, LYNN · 2021 to 2025
$2.1M
S2: Molecular Mechanisms Underlying Fluoroquinolone Susceptibility and ResistanceR01GM115501 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ZECHIEDRICH, LYNN · 2015 to 2018
$1.7M
NIGMS NIH HHS R01 GM115501NIGMS NIH HHS R35 GM141793
6 · The paper itself

Abstract

The respiratory syncytial virus (RSV) fusion (F) protein undergoes two furin-cleavage events to become fusion competent, resulting in the release of a twenty-seven amino acid peptide (p27). Recent studies indicate that the p27 region of the F protein was an immunodominant antigen in young children. In this study, we evaluated the kinetics of the serum antibody response to the p27 peptide following natural RSV reinfection in adults. Nineteen healthy adults under sixty-five years of age were enrolled during the 2018-2019 RSV season in Houston, TX. Blood was collected at three study visits and RSV infection status was defined by changes in neutralizing antibody resulting in three groups: uninfected (n = 12), acutely infected (n = 4), and recently infected (n = 3). Serum IgG and IgA antibodies against RSV/A and RSV/B p27 peptides were measured by enzyme-linked immunosorbent assays, and serum p27-like antibodies were detected by a p27 competitive antibody assay. Anti-p27 antibodies were detected in all subjects at each study visit. The measured IgG and IgA anti-p27 antibody levels followed the same pattern as other RSV site-specific and neutralizing antibody responses described for this cohort previously: the uninfected group had stable responses for the duration of the study period, the acutely infected group had a significant increase following RSV infection, and the recently infected group had a decrease in anti-p27 antibody during the study period. These results indicate that antibodies to the p27 region of the F protein are generated following natural RSV reinfection and suggest that some of the F protein is potentially in a partially cleaved state on the surface of virions, expanding on the previous assumption that all of p27 is post-translationally released and not present on mature F. Additionally, antibody responses were significantly lower (1.4-1.5-fold) toward RSV/B than to RSV/A p27 at each study visit, despite being an RSV/B dominant outbreak. Understanding the mechanism for the differences in the magnitude of the RSV/A and RSV/B p27 antibody response may enhance our understanding of the intracellular processing of the F protein.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdultAntibodies, NeutralizingAntibodies, ViralAntibody FormationChildChild, PreschoolHumansPeptidesViral Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralPeptidesRespiratory Syncytial Virus VaccinesViral Fusion ProteinsFurin cleavage siteFusion proteinP27 peptidePneumovirusRespiratory syncytial virus

Identifiers

PMID34903371
PMCPMC8755595
OpenAlexW4200182864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.